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ABSTRACT: We report a case of Ph-positive chronic myelocytic leukemia in blastic phase in an 1 I-year- 
old boy with Down syndrome. Monosomy 7 was the only additional chromosomal anomaly in the blas- 
tic clone. Fluorescence in situ hybridization analysis on interphase nuclei with a centromeric probe spe- 
cific to chromosome 7 proved to be efficient in disease monitoring, and showed, together with the 
results of  chromosome analysis on metaphases, that B-lymphocytes at the origin of  an EBV-established 
line were not part of  the leukemic lone. The study of DNA polymorphisms showed that the origin of  the 
constitutional tr isomy 21 was a maternal anaphase I nondisjunction, that the chromosome 7 lost in the 
blastic marrow clone was the maternal one, and led us to postulate that the mother's chromosomes are 
prone to impairment of  normal disjunction. The study of  allelic losses of  chromosome 7 loci proved to 
be a further possibil ity for disease monitoring. 0 Elsevier Science Inc., 1997 
INTRODUCTION 
Monosomy 7 is a frequently acquired clonal abnormality 
in acute myeloid leukemias (AML), and in preleukemic 
myelodysplast ic syndromes (MDS), both in adults and in 
children. It is associated with typical cl inical course, prog- 
nostic implications, and hematologic features, so that it is 
possible to describe a specific myeloprol i ferative disorder 
associated with this chromosome anomaly [1, 2], and 
some authors termed this disorder "monosomy 7 syn- 
drome" (M7S) [3, 4]. The existence of this M7S was gener- 
ally accepted in the classif ications of chi ldhood MDS [5]. 
Monosomy 7 is also found in the blastic phase (BP) of 
chronic myelocytic leukemia (CML), where it is an addi- 
tional change to the Phi ladelphia chromosome (Ph) in 
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4.4% of the cases (personal observation on 137 cases, 
unpublished); a similar incidence was reported by Rowley 
and Testa [6]. 
Here we report on a Down syndrome subject with CML 
in BP and monosomy 7. The cytogenetic and molecular 
data of this case raised a number of points worthy of dis- 
cussion. 
Case Report 
B. C., male, born in 1983, was the first son of unrelated 
parents (mother's age 23; father's age 24) and was diagnosed 
to be affected with Down syndrome at birth. The clinical 
picture was typical and a chromosome analysis confirmed 
the presence of tr isomy 21. 
In October 1994 the finding of leukocytosis (WBC 36 x 
106/ml) and increased LDH (2,600 mU/ml) led to an exam- 
ination of the bone marrow, which was hypercel lular with 
atypical myelocytes and metamyelocytes, undifferentiated 
blasts, dyserythropoiesis, and dysmegakaryocytopoiesis. 
This finding, together with the results of chromosomal 
and molecular analysis, led to a diagnosis of Ph-positive 
CML. Hydroxyurea therapy was started, but a marrow con- 
trol in January 1995 revealed a relevant increase of blasts 
(50% of the cells), and, together with immunologic and 
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cytochemica l  data, indicated a progression to BP. A course 
of intensive chemotherapy  was admin istered with only 
partial results (30 to 40% blasts in the bone marrow after 
the first cycle, 5% after the second). In the fo l lowing 
months  the disease progressed wi th  short per iods of par- 
tial remission,  a fungal b ronchopneumonia  was diagnosed 
in December 1995, and the boy died in the same month  be- 
cause of massive lung hemorrhage.  
In 1990 the mother  had a second pregnancy, prenatal  
diagnosis was per formed through amniocentesis ,  and the 
result indicated a karyotype 47,XY,+21. The pregnancy 
was then terminated. In 1995 a third pregnancy, monitored 
by prenatal diagnosis, led to the birth of a healthy male. 
Table 2 Results of FISH analysis wi th  chromosome 7 
centromeric  probe on nucle i  from BM samples, 
EBV-establ ished lymphoblasto id  l ine (LL), 
and controls 
No. spots (%) 
No. 
Material nuclei 0 1 2 3 
Control 1 460 2 16(3%) 440(95%) 2 
Control 2 453 1 11(2%) 440(97%) 1 
BM onset 581 38(6%) 443(76%) 100(17%) - -  
Control 3 650 27(4%) 71(11%) 551(85%) 1 
BM remission 1277 47(4%) 314(25%) 908(71%) 8 
LL 536 17(3%) 42(8%) 463(86%) 14 
CYTOGENETIC STUDIES 
Chromosome analyses were per formed on bone marrow 
(BM) direct preparat ions and 24 hour  to 48 hour  cultures, 
and on per ipheral  b lood (PB) unst imulated cultures with 
standard techniques.  Two acquired anomal ies were found 
in BM and PB in addit ion to the const i tut ional  t r isomy 21: 
a Ph chromosome by standard translocat ion t(9;22), and a 
monosomy 7 in addi t ion to the Ph, both present through- 
out the entire course of the disease. The results are shown 
in Table 1. 
F luorescence in situ hybr id izat ion (FISH) analysis was 
made at the onset of the disease (October 1994), and after 
the po lychemotherapy  of the BP had started and a partial 
remission had been obtained (February 1995). Probe pZ7.6B 
(a gift of Professor M. Rocchi,  Bari), wh ich  hybr id izes spe- 
cif ical ly to centromeric  a lphoid  sequences of chromosome 
7 at conven ient  str ingency condit ions,  was used according 
to standard procedures on nuclei  from bone marrow sam- 
ples and from a lymphoblasto id  l ine establ ished wi th  EBV 
in June 1995: the karyotype of this cell l ine was consis- 
tently 47,XY,+21 (66 mitoses analyzed). Appropr iate  con- 
trols were added to the two FISH exper iments  (at onset 
and remission),  and all the results are l isted in Table 2. 
MOLECULAR STUDIES 
The origin of the extra chromosome 21 was invest igated 
compar ing po lymorph isms of the pat ient and of his par- 
ents. Both RFLP on Southern exper iments  and STR by 
Table I Results of chromosome analyses 
No. mitoses 
Date Material +21 +21,Ph +21,Ph, 7 
10/17/94 BM - -  1 3 
11/16/94 PB - -  3 12 
1/11/95 BM - -  - -  13 
2/1/95 BM 41 - -  1 
3/7/95 BM 39 - -  1 
4/4/95 BM 1 - -  27 
6/21/95 BM - -  - -  12 
6/21/95 PB - -  - -  15 
PCR and electrophoresis  were analyzed, according to stan- 
dard methods.  The results wi th  the interpretat ion of the 
origin for each marker are l isted in Table 3. Al le le distri- 
but ion at loci D21S258 and D21S l l  indicated a maternal  I 
nondis junct ion.  
We studied some loci on chromosome 7 by STR poly- 
morph ism analysis to obtain ev idence of al lel ic loss in the 
bone marrow, and to identi fy if the maternal  or paternal 
chromosome 7 had been lost. The analysis was repeated 
four t imes, at the onset of the disease, at the beginning of 
the BP, at partial remission,  and at relapse, when highly 
different proport ions of monosomic  7 cells were present in 
the marrow (Tables 1 and 2). The same study was made on 
WBC of the pat ient at remiss ion and at relapse, and on his 
parents'  WBC. Informative po lymorph isms are shown in 
Figure 1. For each of the three loci one allele was clearly 
less intense or not ev ident  in the BM of onset (lane 6) and 
of BP (lane 5), but not at remiss ion (lane 4: BM; lane 2: 
PB). The al lel ic loss was again ev ident  both in the BM and 
PB obtained at relapse (data not shown). The al lele absent 
or of lower intensity was consistent ly the maternal  one. 
DISCUSSION 
The CML of the pat ient here reported was moni tored by 
repeated rout ine chromosome analyses, but informat ion 
Table 3 Results of po lymorph ism analysis of the l isted 
chromosome 21 loci 
Locus Proband Mother Father Error type 
D21S215 122 12 12 NI 
D21S258 124 24 13 M I 
D21S120 122 12 22 M I/P I, II 
M21($13) TaqI + + + + NI 
D21S192 122 22 12 M I, II/P I 
1H($52) BgIII + + + + + + + NI 
D21Sll  124 12 34 M I 
36B(S11) TaqI -+  +-  +-  N! 
D21S213 112 11 12 M I, II/P I 
H8($17) BgIII + + - + - + - NI 
102($25) HindlII + . . . .  + + M I, II 
D21S212 112 11 12 M I, II/P I 
Abbreviations: BM. bone marrow; PB, peripheral blood unstimulated cul- Abbreviations: NI, not informative; M I, II, P I, II. nondisjunction at mater- 
tures, hal or paternal meiosis I or II. 
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Figure 1 Results of chromosome 7 STR analysis of the loci 
indicated. Lane 1: Mother's WBC; lane 2: proband's WBC at 
remission; lane 3: father's WBC; lane 4-6: proband's BM at remis- 
sion, BP, and CML onset, respectively. 
more relevant for the clinical management was obtained 
when FISH analysis of nuclei was added. The relevance of 
interphase analyses in monosomy 7 associated with AML 
and MDS has been already stressed in the literature [7-9]. 
In our case, where monosomy 7 is additional to the Ph, it 
is noteworthy that we demonstrated it at the beginning of 
the disease, with a considerable advance (three months) to 
a clinically overt BP: at the onset of CML, when only 4 
mitoses were seen at chromosome analysis, and 3 of them 
with monosomy 7 (Table 1), 76% of an informative num- 
ber of BM nuclei (581) were demonstrated to be mono- 
somic (Table 2). In fact the -7  clone led then to the BP. 
When partial remission was obtained, and 1 cell out of 42 
showed a Ph and -7  at chromosome analysis (Table 1), 
Table 4 Comparison among chromosome 7 allelic loss, 
chromosome analysis results, and FISH 
on nuclei 
Date Allelic Metaphases Nuclei 
(disease phase) Material loss - 7 - 7 
10/17/94 BM + 3/4 76% 
(CML onset) 
1/11/95 BM + 13/13 NE 
(BP) 
2/1/95 BM - 1/42 25% ° 
(remission) 
6/21/95 BM + 12/12 NE 
(relapse) 
PB + 15/15 NE 
Abbreviations: BM, bone marrow; PB, peripheral blood unstimulated cul- 
tures; NE, not examined. 
aNote that the control results in this experiment showed 11% nuclei with 
one signal (Table 2): the proportion of -7  BM nuclei should be considered 
lower accordingly. 
FISH data revealed that a significant proportion of BM 
cells belonged to the -7  clone (Table 2), which was pre- 
dictive of the relapse that in fact soon took place. Thus 
interphase monitoring of the blastic -7  clone proved to be 
of prognostic relevance. 
B-lymphocytes are thought o be part of the leukemic 
clone in Ph-positive CML [10], whereas conflicting evi- 
dence is available on the involvement ofB-lymphocytes in
-7  AML/MDS [11-13]. The results of chromosome analy- 
sis and FISH nuclei score made on the EBV-established 
line of our patient indicate that the B-lymphocytes that 
gave origin to this line did not share a Ph chromosome, 
nor monosomy 7 with the - 7 blastic marrow clone. 
The origin of the constitutional trisomy 21 of our pa- 
tient was maternal anaphase I nondisjunction (Table 3), as 
in 73.11% of the cases [14]. The chromosome 7 lost in the 
blastic marrow clone was the maternal one (Fig. 1). Avail- 
able data concerning the parental origin of chromosome 7 
loss in 21 children with AML/MDS showed the loss of the 
maternal 7 in 11, of the paternal in 10 [15, 16]. Our case is 
the first one in which the origin of chromosome 7 loss is 
investigated in CML, where it should be considered a sec- 
ondary event. If the chromosome 7 is lost as consequence 
of mitotic nondisjunction, and if we take into account he 
young age of the mother (23 years) and her subsequent 
pregnancy with a trisomic 21 fetus, we may postulate that 
the mother's chromosomes are prone to impairment of 
normal disjunction. The existence of a constitutional pre- 
disposition to nondisjunction is supported by the known 
risk of recurrence of aneuploidies after trisomy 21, by dou- 
ble aneuploidies, by some mitotic mutants described in 
the literature with multiple somatic, and even clonal, ane- 
uploidies [17]. A similar etiology might account also for 
multiple aneuploidies not infrequently found in leukemic 
cells and not associated with any structural abnormalities. 
The evidence of allelic ~oss of chromosome 7 obtained 
in our patient is compared with cytogenetic and FISH data 
in Table 4. Allelic loss was evident at CML onset, and at 
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BP, but  not dur ing remission,  and again demonstrable at 
relapse both on BM and PB. Thus, al lel ic loss correlated 
wel l  w i th  cytogenetic data, and proved to be a further pos- 
sibi l i ty for disease monitor ing.  
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